Ovid Therapeutics (OVID) Non-Current Assets (2016 - 2026)

Ovid Therapeutics' Non-Current Assets history runs 11 years deep, the most recent figure standing at $65.5 million for Q1 2026.

• Quarterly Non-Current Assets rose 83.26% year-over-year to $65.5 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $212.4 million (up 45.5% YoY) and the FY2025 annual result came in at $76.6 million, up 111.35% from the prior year.
• Non-Current Assets was $65.5 million for Q1 2026 at Ovid Therapeutics, down from $76.6 million in the prior quarter.
• Across five years, Non-Current Assets topped out at $76.6 million in Q4 2025 and bottomed at $21.0 million in Q1 2022.
• A 5-year average of $36.1 million and a median of $35.0 million in 2025 frame the typical range for Non-Current Assets.
• Annual changes were most pronounced in 2022 — Non-Current Assets surged 2546.02% — and 2025, when it retreated 7.05%.
• Ovid Therapeutics' Non-Current Assets stood at $23.9 million in 2022, then surged by 44.14% to $34.4 million in 2023, then grew by 5.22% to $36.2 million in 2024, then jumped by 111.35% to $76.6 million in 2025, then dropped by 14.48% to $65.5 million in 2026.
• Business Quant data shows OVID's Non-Current Assets at $65.5 million in Q1 2026, $76.6 million in Q4 2025, and $35.0 million in Q3 2025.